Condition: Systemic Lupus Erythematosus · Idiopathic Inflammatory Myopathies · Rheumatoid Arthritis · Sponsor: AstraZeneca
The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur at: Screening, Days 1-4, 8, 15, 22, 30, 60, 90, 120, 150, and 180 in Part 1, Screening, Days 1-4, 8-11, 15, 22, 29, 43, 60, 90, 120, 150, and 180 in Part 2.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Anniston, Alabama, United States | Recruiting |
| Research Site | Birmingham, Alabama, United States | Withdrawn |
| Research Site | La Jolla, California, United States | Not Yet Recruiting |
| Research Site | Sacramento, California, United States | Not Yet Recruiting |
| Research Site | Iowa City, Iowa, United States | Recruiting |
| Research Site | Omaha, Nebraska, United States | Not Yet Recruiting |
| Research Site | Chapel Hill, North Carolina, United States | Not Yet Recruiting |
| Research Site | Hamilton, Ontario, Canada | Not Yet Recruiting |
| Research Site | Sherbrooke, Quebec, Canada | Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Shanghai, China | Recruiting |
| Research Site | Wuhan, China | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06916806